PDCD1 and melanoma: We hypothesized that ziv-aflibercept would induce anti-tumor effects via its anti-angiogenic activity, and that combined with pembrolizumab could attenuate resistance to PD-1 inhibitors and improve clinical outcomes rate in advanced melanoma patients.